Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Gastric cancer (GC) is still an important global healthcare problem, and in absolute figures it is going to remain at the present level in foreseeable future. In general, survival of patients with GC is poor mainly due to advanced-stage diagnosis. Early-stage GC can be cured by endoscopic resection or less invasive surgical treatment. Unfortunately, there is no appropriate screening strategy available for global application. This article provides a description of established national and regional GC screening programs and the screening modalities used. This review also summarizes current approaches to develop cancer-screening biomarkers. Although candidates with initial promising results have been suggested, moving discovery into clinical practice is still a major challenge. Well-designed biomarker studies, with systematic validation steps, are needed to decrease the burden of this fatal disease.

Original publication

DOI

10.1016/j.bpg.2014.09.005

Type

Journal

Best practice & research. Clinical gastroenterology

Publication Date

12/2014

Volume

28

Pages

1093 - 1106

Addresses

Faculty of Medicine, University of Latvia, 6 Linezera iela, LV1006 Riga, Latvia. Electronic address: cei@latnet.lv.

Keywords

Humans, Stomach Neoplasms, Early Detection of Cancer, Global Health, Biomarkers, Tumor